Brokers Set Expectations for Aktis Oncology FY2025 Earnings

Aktis Oncology (NASDAQ:AKTS) – Stock analysts at HC Wainwright issued their FY2025 EPS estimates for Aktis Oncology in a research report issued to clients and investors on Monday, March 9th. HC Wainwright analyst R. Burns expects that the technology company will earn ($2.39) per share for the year. HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Aktis Oncology’s current full-year earnings is ($0.43) per share. HC Wainwright also issued estimates for Aktis Oncology’s Q4 2025 earnings at ($1.00) EPS, Q1 2026 earnings at ($0.64) EPS, Q2 2026 earnings at ($0.71) EPS, Q3 2026 earnings at ($0.77) EPS, Q4 2026 earnings at ($0.83) EPS, FY2026 earnings at ($2.95) EPS and FY2027 earnings at ($3.71) EPS.

Several other equities analysts also recently commented on the company. Bank of America initiated coverage on Aktis Oncology in a research report on Tuesday, February 3rd. They issued a “buy” rating and a $34.00 target price on the stock. Leerink Partners initiated coverage on Aktis Oncology in a research report on Tuesday, February 3rd. They set an “outperform” rating and a $31.00 target price for the company. TD Cowen initiated coverage on shares of Aktis Oncology in a research report on Tuesday, February 3rd. They set a “buy” rating on the stock. Wall Street Zen upgraded shares of Aktis Oncology to a “hold” rating in a research note on Saturday, January 17th. Finally, JPMorgan Chase & Co. started coverage on Aktis Oncology in a research report on Tuesday, February 3rd. They issued an “overweight” rating and a $30.00 target price for the company. Five research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $31.25.

Aktis Oncology Price Performance

NASDAQ AKTS opened at $18.98 on Wednesday. The firm has a 50 day moving average of $19.76. Aktis Oncology has a 12 month low of $16.80 and a 12 month high of $29.16.

Insider Activity at Aktis Oncology

In related news, Director Ecor1 Capital, Llc bought 2,222,222 shares of the company’s stock in a transaction that occurred on Monday, January 12th. The stock was bought at an average cost of $18.00 per share, for a total transaction of $39,999,996.00. Following the acquisition, the director directly owned 4,348,658 shares of the company’s stock, valued at $78,275,844. The trade was a 104.50% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Vida Ventures Ii, Llc bought 835,000 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The stock was acquired at an average cost of $18.00 per share, for a total transaction of $15,030,000.00. Following the completion of the purchase, the insider directly owned 5,671,825 shares of the company’s stock, valued at $102,092,850. The trade was a 17.26% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought 6,117,776 shares of company stock valued at $110,119,968 in the last ninety days.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.